Prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant Mycoplasma genitalium
Journal of Antimicrobial Chemotherapy · 03.01.2025 · 80 (1) · 247-253
DOI: 10.1093/jac/dkae403 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 05.11.2024. Verfasst von Naokatsu Ando und 12 weiteren Autor:innen. Beteiligte Einrichtung: AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Mycoplasma genitalium, Mycoplasma Infections, Anti-Bacterial Agents, Fluoroquinolones. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Center for Global Health and Medicine.
Abstract (Originalsprache)
Background
Mycoplasma genitalium, which causes sexually transmitted diseases, is increasingly resistant to key antibiotics such as macrolides and quinolones, posing a challenge for treatment.
Objectives
To assess the effectiveness of prolonged sitafloxacin and doxycycline combination therapy as a new alternative treatment strategy for highly drug-resistant M. genitalium strains Methods A prospective cohort study was conducted at the National Center for Global Health and Medicine, Tokyo, Japan, from 1 January 2020 to 31 October 2022. Patients with M. genitalium urogenital or rectal infections and those who did not receive the initial sitafloxacin monotherapy were included. Patients were administered sitafloxacin and doxycycline for 21 days as salvage therapy. M. genitalium isolates were tested for parC, gyrA and 23S rRNA resistance-associated mutations.
Results
Twenty-seven patients received the combination therapy. All M. genitalium strains available for resistance analysis had parC (24/24) and macrolide resistance-associated (25/25) mutations, and 68% (17/25) had gyrA mutations. The overall cure rate was 77.8%. For strains with concurrent parC and gyrA mutations, the cure rate was 68.8% (P = 0.053) compared with that for monotherapy (37.5%).
Conclusions
Prolonged combination therapy is highly effective against M. genitalium strains with concurrent parC and gyrA mutations. Future research should focus on establishing the optimal treatment duration and monitoring the risk of resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.
- Department of Microbiology, Tokyo Metropolitan Institute for Public Health, Tokyo, Japan.
ORCID-Profile: Naokatsu Ando, Daisuke Mizushima, Hiroaki Kubota, Koji Watanabe
Förderung
- National Center for Global Health and Medicine
Zitieren
APA
Ando, N., Mizushima, D., Takano, M., Mitobe, M., Kobayashi, K., Kubota, H., Miyake, H., Suzuki, J., Sadamasu, K., Aoki, T., Watanabe, K., Oka, S., & Gatanaga, H. (2025). Prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant Mycoplasma genitalium. Journal of Antimicrobial Chemotherapy, 80(1), 247-253. https://doi.org/10.1093/jac/dkae403
Vancouver
Ando N, Mizushima D, Takano M, Mitobe M, Kobayashi K, Kubota H, et al. Prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant Mycoplasma genitalium. Journal of Antimicrobial Chemotherapy. 2025;80(1):247-253. doi:10.1093/jac/dkae403
BibTeX
@article{Ando2025,
author = {Ando, Naokatsu and Mizushima, Daisuke and Takano, Misao and Mitobe, Morika and Kobayashi, Kai and Kubota, Hiroaki and Miyake, Hirofumi and Suzuki, Jun and Sadamasu, Kenji and Aoki, Takahiro and Watanabe, Koji and Oka, Shinichi and Gatanaga, Hiroyuki},
title = {Prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant Mycoplasma genitalium},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {1},
pages = {247--253},
doi = {10.1093/jac/dkae403}
}
EUVIMED